Bactiguard Holding AB (Bactiguard) (STO:BACTIB), a Swedish medical device company developing and supplying infection prevention solutions, reported on Wednesday net profit of SEK1,6m, or EPS of SEK0,05, for the first quarter of 2020, from January 2020 to March 2020.
This was an improvement over net loss of SEK3,4m, or SEK0.10 per share, in Q1 2019.
Revenues for the quarter amounted to SEK48,1m, up by 42% as compared with SEK33,9m in Q1 2019. The increase was 36% after adjustment for currency.
Reportedly, Bactiguard's sales and earnings were positively affected by COVID-19. The spread of the pandemic has not had any significant negative effects or caused interruptions to the business.
According to the company, the COVID-19 pandemic has highlighted the urgent need for infection prevention. This has led to an increased interest in Bactiguard and generated strong sales from mid-March 2020. Total revenues increased by over 40% in the quarter and EBITDA doubled, generating an EBITDA margin of 30% and a positive net result.
(EUR1.00=SEK10.64)
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025